Recordati S.a. Chemical and Pharmaceutical Company

Recordati Ireland Limited

Recordati S.a.

Pharmaceutical Company

Recordati S.a. Chemical

Recordati, S.a., Chemical and Pharmacueticals Company

Recordati Industria Chimica E Farmaceutica S.p.a.

Amedeo Leonardi

Gianni Motta

Carlo Riva

Rodolfo Testa

Dante Nardi

Elena Poggesi

Luciano Guarneri

Gabriele Graziani

Giorgio Bianchi

Giorgio Sironi

Davide Graziani

Pietro Cazzulani

Fausto Bonifacio

Patrizia Angelico

Markus Von Raumer

Carlo De Toma

Alberto Catto

Matteo Longhi

Fabio Berlati

Renzo Pennini

Gianluca De Iasi

Katia Dimitrova Karamfilova

Carlo Boi

Abraham Sartani

Francesco Campana

Luc Jacquet

Matteo Marco Longhi

The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.

Spiroheterocyclic compounds as mGlu5 antagonists

This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).

Heterocyclic derivatives as M-GLU5 antagonists

The invention provides a substantially pure amorphous lercanidipine hydrochloride having a purity of at least 95% pure, preferably at least about 97% pure, more preferably at least about 99% pure, and still more preferably at least about 99.5% pure. The invention further relates to methods of preparing substantially pure amorphous lercanidipine, as well as methods of providing rapid relief from hypertension by administering the substantially pure amorphous lercanidipine hydrochloride of the present invention to a patient in need of such treatment.

Amorphous lercanidipine hydrochloride and uses thereof

The present invention relates to new addition salts of lercanidipine comprising lercanidipine and an acid counterion wherein the acid counterion is selected from the group consisting of: (i) inorganic acids, (ii) sulfonic acids, (iii) monocarboxylic acids, (iv) dicarboxylic acids, (v) tricarboxylic acids, and (vi) aromatic sulfonimides, with the proviso that said acid counterion is not hydrochloric acid.

Lercanidipine salts

N,N-Disubstituted diazocycloalkanes of the formula I 

N,N-disubstituted diazocycloalkanes

Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the &#x3b1;-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.

Use of selective antagonists of the &#x3b1;1B-adrenergic receptor for improvement of sexual dysfunction

Disclosed herein are novel compounds and methods for the treatment of disorders of the lower urinary tract. The novel compounds are diarylalkylpiperazine derivatives. The methods comprise the administration of the novel compounds of the invention, and other compounds that bind to 5HTreceptors, for treating disorders of the lower urinary tract.

Diarylalkylpiperazines active on the lower urinary tract

The invention describes novel lercanidipine crude Forms (A) and (B), novel lercanidipine hydrochloride crystalline Forms (I) and (II) obtained from said crude Forms, pharmaceutical, antihypertensive compositions containing as active agent at least one of the lercanidipine hydrochloride crystalline Forms (I) and (II) and methods of use thereof.

Crude and crystalline forms of lercanidipine hydrochloride

The invention relates to novel N-(substituted phenyl)-N&prime;-&lsqb;&ohgr;-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl&rsqb;piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.

Isoxazolecarboxamide derivatives

The invention relates to novel N-(substituted phenyl)-N&prime;-&lsqb;&ohgr;-(5-substituted-7-oxo-7H-thieno&lsqb;3,2-b&rsqb;pyran-3-carbonylamino)alkyl&rsqb;piperazines their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neutogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.

Thienopyranecarboxamide derivatives

The treatment of neuromuscular dysfunction of the lower urinary tract by compounds which selectively inhibit the COX-2 isozyme is described. The compounds concerned inhibit the COX-2 isozyme with a potency at least 10-fold, and preferably at least 100-fold, greater than their potency on the COX-1 isozyme.

Use of selective COX-2 inhibitors for the treatment of urinary incontinence

The invention relates to novel benzopyran derivatives of formula I, their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS), neurogenic lower urinary tract dysfunction (NLUTD), and other conditions.

Benzopyran derivatives

The present invention is directed to novel 1-(N-phenylaminoalkyl)piperazine derivatives substituted at the position 2 of the phenyl ring. Pharmaceutical compositions comprising the compounds of the invention also are contemplated. The compounds of the present invention also are contemplated for use in treating neuromuscular dysfunction of the lower urinary tract in a mammal.

1-(N-phenylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring

The invention relates to novel N-(substituted phenyl)-N&prime;-&lsqb;&ohgr;-(5-substituted-7-oxo-7H-thieno&lsqb;3,2-b&rsqb;pyran-3-carbonylamino)alkyl&rsqb;piperazines their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha -adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD). The compounds are also useful in the treatment of excessive intraocular pressure, cardiac arrhythmia, erectile dysfunction, sexual dysfunction, and for inhibiting cholesterol synthesis or reducing sympathetically mediated pain.

The invention relates to novel N-(substituted phenyl)-N&prime;-&lsqb;&ohgr;-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl&rsqb;piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions.

Growing community of inventors

Milan, Italy

Amedeo Leonardi